B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients

Journal of Neuroimmunology

Volumn 272, Issue 1-2, 2014, Pages 86-90

  Rovituso, Damiano ^a,b   Heller, Stefanie ^a   Schroeter, Michael ^a   Kleinschnitz, Christoph ^c   Kuerten, Stefanie ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

B cells; B1 cells; Flow cytometry; MS

Indexed keywords

BETA INTERFERON; CD20 ANTIGEN; CD27 ANTIGEN; CD3 ANTIGEN; GLATIRAMER; IMMUNOMODULATING AGENT; LEUKOSIALIN; NATALIZUMAB;

ADULT; ARTICLE; B LYMPHOCYTE; B1 CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MEMORY CELL; MULTIPLE SCLEROSIS; PLASMABLAST; PRIORITY JOURNAL;

B CELLS; B1 CELLS; FLOW CYTOMETRY; MS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; B-LYMPHOCYTE SUBSETS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES;

EID: 84901979227     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.04.008     Document Type: Article

References (21)

1. Bar-Or A., Oliveira E.M., Anderson D.E., Krieger J.I., Duddy M., O'Connor K.C., Hafler D.A. Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state. J. Immunol. 2001, 167:5669-5677.
2. Bar-Or A., Fawaz L., Fan B., Darlington P.J., Rieger A., Ghorayeb C., Calabresi P.A., Waubant E., Hauser S.L., Zhang J., Smith C.H. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?. Ann. Neurol. 2010, 67:452-461.
3. Capolunghi F., Rosado M.M., Sinibaldi M., Aranburu A., Carsetti R. Why do we need IgM memory B cells?. Immunol. Lett. 2013, 152:114-120.
4. Covens K., Verbinnen B., Geukens N., Meyts I., Schuit F., Van Lommel L., Jacquemin M., Bossuyt X. Characterization of proposed human B-1 cells reveals pre-plasmablast phenotype. Blood 2013, 121:5176-5183.
5. + human B1 cell subpopulation stimulates T cells and is expanded in lupus. J. Exp. Med. 2011, 208:2591-2598.
6. Griffin D.O., Rothstein T.L. Human B1 cell frequency: isolation and analysis of human B1 cells. Front. Immunol. 2012, 3:122.
7. Griffin D.O., Rothstein T.L. Human "orchestrator" CD11b(+) B1 cells spontaneously secrete interleukin-10 and regulate T-cell activity. Mol. Med. 2012, 18:1003-1008.
8. Griffin D.O., Holodick N.E., Rothstein T.L. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70- J. Exp. Med. 2011, 208:67-80.
9. Krumbholz M., Meinl I., Kümpfel T., Hohlfeld R., Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008, 71:1350-1354.
10. Lucchinetti C., Brück W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
11. Lucchinetti C.F., Popescu B.F.G., Bunyan R.F., Moll N.M., Roemer S.F., Lassmann H., Brück W., Parisi J.E., Scheithauer B.W., Giannini C., Weigand S.D., Mandrekar J., Ransohoff R.M. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 2011, 365:2188-2197.
12. Perfetto S.P., Chattopadhyay P.K., Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nat. Rev. Immunol. 2004, 4:648-655.
13. Pinna D., Corti D., Jarrossay D., Sallusto F., Lanzavecchia A. Clonal dissection of the human memory B-cell repertoire following infection and vaccination. Eur. J. Immunol. 2009, 39:1260-1270.
14. Planas R., Jelčić I., Schippling S., Martin R., Sospedra M. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur. J. Immunol. 2012, 42:790-798.
15. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.-P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 2005, 58:840-846.
16. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
17. Ramgolam V.S., Sha Y., Marcus K.L., Choudhary N., Troiani L., Chopra M., Markovic-Plese S. B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis. J. Immunol. 2011, 186:4518-4526.
18. Suchanek O., Sadler R., Bateman E.A., Patel S.Y., Ferry B.L. Immunophenotyping of putative human B1 B cells in healthy controls and common variable immunodeficiency (CVID) patients. Clin. Exp. Immunol. 2012, 170:333-341.
19. Tørring C., Petersen C.C., Bjerg L., Kofod-Olsen E., Petersen T., Höllsberg P. The B1-cell subpopulation is diminished in patients with relapsing-remitting multiple sclerosis. J. Neuroimmunol. 2013, 262:92-99.
20. Varkony H., Weinstein V., Klinger E., Sterling J., Cooperman H., Komlosh T., Ladkani D., Schwartz R. The glatiramoid class of immunomodulator drugs. Expert. Opin. Pharmacother. 2009, 10:657-668.
21. Zanotti C., Chiarini M., Serana F., Sottini A., Garrafa E., Torri F., Caimi L., Rasia S., Capra R., Imberti L. Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients. Clin. Immunol. 2012, 145:19-26.